TY - JOUR
T1 - Excess hydrogen sulfide and polysulfides production underlies a schizophrenia pathophysiology
AU - Ide, Masayuki
AU - Ohnishi, Tetsuo
AU - Toyoshima, Manabu
AU - Balan, Shabeesh
AU - Maekawa, Motoko
AU - Shimamoto-Mitsuyama, Chie
AU - Iwayama, Yoshimi
AU - Ohba, Hisako
AU - Watanabe, Akiko
AU - Ishii, Takashi
AU - Shibuya, Norihiro
AU - Kimura, Yuka
AU - Hisano, Yasuko
AU - Murata, Yui
AU - Hara, Tomonori
AU - Morikawa, Momo
AU - Hashimoto, Kenji
AU - Nozaki, Yayoi
AU - Toyota, Tomoko
AU - Wada, Yuina
AU - Tanaka, Yosuke
AU - Kato, Tadafumi
AU - Nishi, Akinori
AU - Fujisawa, Shigeyoshi
AU - Okano, Hideyuki
AU - Itokawa, Masanari
AU - Hirokawa, Nobutaka
AU - Kunii, Yasuto
AU - Kakita, Akiyoshi
AU - Yabe, Hirooki
AU - Iwamoto, Kazuya
AU - Meno, Kohji
AU - Katagiri, Takuya
AU - Dean, Brian
AU - Uchida, Kazuhiko
AU - Kimura, Hideo
AU - Yoshikawa, Takeo
N1 - Publisher Copyright:
© 2019 The Authors. Published under the terms of the CC BY 4.0 license
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Mice with the C3H background show greater behavioral propensity for schizophrenia, including lower prepulse inhibition (PPI), than C57BL/6 (B6) mice. To characterize as-yet-unknown pathophysiologies of schizophrenia, we undertook proteomics analysis of the brain in these strains, and detected elevated levels of Mpst, a hydrogen sulfide (H2S)/polysulfide-producing enzyme, and greater sulfide deposition in C3H than B6 mice. Mpst-deficient mice exhibited improved PPI with reduced storage sulfide levels, while Mpst-transgenic (Tg) mice showed deteriorated PPI, suggesting that “sulfide stress” may be linked to PPI impairment. Analysis of human samples demonstrated that the H2S/polysulfides production system is upregulated in schizophrenia. Mechanistically, the Mpst-Tg brain revealed dampened energy metabolism, while maternal immune activation model mice showed upregulation of genes for H2S/polysulfides production along with typical antioxidative genes, partly via epigenetic modifications. These results suggest that inflammatory/oxidative insults in early brain development result in upregulated H2S/polysulfides production as an antioxidative response, which in turn cause deficits in bioenergetic processes. Collectively, this study presents a novel aspect of the neurodevelopmental theory for schizophrenia, unraveling a role of excess H2S/polysulfides production.
AB - Mice with the C3H background show greater behavioral propensity for schizophrenia, including lower prepulse inhibition (PPI), than C57BL/6 (B6) mice. To characterize as-yet-unknown pathophysiologies of schizophrenia, we undertook proteomics analysis of the brain in these strains, and detected elevated levels of Mpst, a hydrogen sulfide (H2S)/polysulfide-producing enzyme, and greater sulfide deposition in C3H than B6 mice. Mpst-deficient mice exhibited improved PPI with reduced storage sulfide levels, while Mpst-transgenic (Tg) mice showed deteriorated PPI, suggesting that “sulfide stress” may be linked to PPI impairment. Analysis of human samples demonstrated that the H2S/polysulfides production system is upregulated in schizophrenia. Mechanistically, the Mpst-Tg brain revealed dampened energy metabolism, while maternal immune activation model mice showed upregulation of genes for H2S/polysulfides production along with typical antioxidative genes, partly via epigenetic modifications. These results suggest that inflammatory/oxidative insults in early brain development result in upregulated H2S/polysulfides production as an antioxidative response, which in turn cause deficits in bioenergetic processes. Collectively, this study presents a novel aspect of the neurodevelopmental theory for schizophrenia, unraveling a role of excess H2S/polysulfides production.
KW - energy metabolism
KW - epigenetics
KW - hydrogen sulfide and polysulfides
KW - prepulse inhibition
KW - proteomics
UR - http://www.scopus.com/inward/record.url?scp=85074585841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074585841&partnerID=8YFLogxK
U2 - 10.15252/emmm.201910695
DO - 10.15252/emmm.201910695
M3 - Article
C2 - 31657521
AN - SCOPUS:85074585841
SN - 1757-4676
VL - 11
JO - EMBO Molecular Medicine
JF - EMBO Molecular Medicine
IS - 12
M1 - e10695
ER -